Gold glistens brighter in a chaotic world: podcast
The yellow metal's value rose by over a third in the past year, as volatile markets and a sliding dollar highlight the oldest safe haven. On this Viewsroom podcast, Breakingviews columnists debate the degree to which investors may be seeking a hedge against the whims of states.
Follow @aimeedonnellan and @JMAGuilford on X
(The hosts are Reuters Breakingviews columnists. The opinions expressed are their own.)
Further Reading
Gold's golden moment dazzles better-value rivals
Gold shines brighter as red, white and blue dull
Surging gold gives Richemont pricing dilemma
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
25 minutes ago
- Reuters
Air Canada profit falls on weak US travel demand
July 28 (Reuters) - Air Canada ( opens new tab reported a drop in second-quarter profit on Monday, weighed down by weak passenger traffic to its key U.S. market amid strained trade relations between the two countries. Canada's largest carrier reported a profit of C$0.60 ($0.4368) during the second quarter, compared with C$0.98 per share, a year ago. ($1 = 1.3735 Canadian dollars)
Reuters
25 minutes ago
- Reuters
Bristol Myers, Bain Capital form new company to develop immunology drugs
July 28 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials. Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success. The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, senior vice president of business development at Bristol Myers. Daniel Lynch, a seasoned pharmaceutical executive, will take on the roles of executive chairman and interim CEO of the new company, while Bristol Myers' chief research officer Robert Plenge is set to join the board alongside Bain Capital partners. Canada Pension Plan Investment Board also participated in the financing round.
Reuters
25 minutes ago
- Reuters
Universal Health Services beats quarterly profit estimates on higher medical care demand
July 28 (Reuters) - U.S. hospital operator Universal Health Services (UHS.N), opens new tab beat Wall Street estimates for second-quarter profit on Monday, driven by sustained demand for medical care services. Health insurers have flagged elevated demand and costs in individual Affordable Care Act (Obamacare) and Medicaid plans for low-income individuals, which could benefit hospital operators. Last week, larger peer HCA Healthcare (HCA.N), opens new tab beat quarterly profit estimates but saw its shares decline amid concerns over impending changes to Medicaid and Obamacare insurance plans under the Trump administration. Universal Health's same-facility adjusted admissions increased by 2% at acute care hospitals during the quarter, while admissions at behavioral healthcare facilities grew by 0.4%. The company now sees its 2025 revenue to be between $17.10 billion and $17.31 billion, compared to the previously expected range of $17.02 billion to $17.36 billion. Analysts, on average, expect 2025 revenue of $17.14 billion, according to data compiled by LSEG data. For the quarter ended June 30, the King Of Prussia, Pennsylvania-based company reported an adjusted profit of $5.43 per share, beating estimates of $4.92 per share. Investors are currently focused on how hospital operators will address potential tariffs affecting global supply chains for medical devices and surgical equipments. The sector is also preparing for the expiry of Obamacare subsidies next year, a change expected to impact patient coverage, raise insurance premiums and reduce enrollment numbers, potentially leaving hospitals responsible for increased uncompensated care costs.
